San Diego, CA, United States of America

Alexandre V Lebedev

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Genta Incorporated. Active years: 2000.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 96(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Alexandre V Lebedev

Introduction

Alexandre V Lebedev is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly through his innovative work on chimeric oligonucleoside compounds. His research focuses on the development of compounds that can activate RNaseH-mediated cleavage of target ribonucleic acid sequences, which has implications for treating various disease conditions.

Latest Patents

Lebedev holds 1 patent for his invention titled "Chimeric oligonucleoside compounds." This patent details methods of preparing and formulating these compounds, emphasizing their utility in medical applications.

Career Highlights

Throughout his career, Alexandre has worked with several prominent companies in the biotechnology sector. Notably, he has been associated with Genta Incorporated and Trilink Biotechnologies, Inc. His work in these organizations has contributed to advancements in the understanding and application of oligonucleoside compounds.

Collaborations

Lebedev has collaborated with esteemed colleagues, including Lyle J Arnold, Jr and Mark A Reynolds. These partnerships have fostered a collaborative environment that enhances innovation and research in his field.

Conclusion

Alexandre V Lebedev's contributions to biotechnology through his patented innovations highlight the importance of research in developing therapeutic solutions. His work continues to influence the landscape of medical science and biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…